CorMedix opened lower at $5.15, compared with its previous close of $5.30. In the last trading session, the stock traded between $4.82 and $5.49. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in CorMedix is now worth
$ 91.63
Resulting in a loss of
$ 8.37 (8.37%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.46 (-8.72%)
Day High
$5.49
Day Low
$4.82
Day Open
$5.15
Prev Close
$5.30
Volume
32,31,681
1W Return
-14.45%
1M Return
-35.08%
3M Return
-33.68%
6M Return
-36.84%
1Y Return
-56.76%
Fundamentals
Market Cap ($ Mn)
377
PE Ratio
4.05
PB Ratio
1.40
PEG Ratio
0.02
ROE
67.96%
ROCE
44.06%
EPS (TTM)
$0.33
Investment Returns
1 Week
-14.45%
1 Month
-35.08%
3 Months
-33.68%
6 Months
-36.84%
9 Months
-34.89%
Financials
Quarterly
All values in $ Mn
39.1
Mar 25
39.7
Jun 25
104.3
Sep 25
128.6
Dec 25
127.4
Mar 26
99.3
Jun 26
Updates
12Nov
CorMedix Q3FY26 Results: Revenue beats consensus at $54.5 million
Q3 2026 revenue reached $54.5 million, beating consensus estimates. Full-year 2026 adjusted EBITDA guidance narrowed to $130-$140 million. Heron acquisition expected to double non-DefenCath revenue base in 2027. Cash position stands at $355 million with no external financing needed for deal upfront. DefenCath 2027 guidance deferred due to CMS reimbursement methodology changes.
Today
10Nov
Needham raises Cormedix price target to $14, maintains Buy rating
Needham maintains a Buy rating on Cormedix. Price target raised from $12 to $14. Analyst Serge Belanger issued the update.
2 days ago
2Nov
Needham maintains Buy on Cormedix, cuts price target to $12
Needham maintains a Buy rating on Cormedix. Price target reduced from $15 to $12. Analyst Serge Belanger issued the update.
10 days ago
19Oct
FDA grants Priority Review to CorMedix REZZAYO sNDA, PDUFA Q1 2027
FDA granted Priority Review to CorMedix's sNDA for REZZAYO prophylaxis. PDUFA target action date set for Q1 2027. Promotional launch targeted for H2 2027 if approved. Rezafungin has orphan drug exclusivity through 2035.
24 days ago
13Aug
CorMedix Q2 revenue hits $101.9M; DEFSEC up 92% YoY
CorMedix Therapeutics posted Q2 revenue of $101.9M with $256.7M cash on hand. DEFSEC Technologies saw fiscal Q3 revenue jump 92% YoY to C$2.72M. XChange proposed acquiring First Cycle for AI capabilities, while Iveda secured federal drone procurement access via GlobalMed.
CorMedix received preliminary court approval for its derivative settlement on July 24. The U.S. District Court set a final hearing for September 23 to determine permanent approval of the agreement. This step advances the resolution of the litigation, with further details expected as the final hearing approaches.
